5 February 2026: Mankind Pharma announced its financial results for the third quarter and nine months ended 31st December 2025. The information mentioned in this release is based on consolidated financial statements.
Rajeev Juneja – Vice Chairman & Managing Director said, “Mankind’s revenue increased 11.5% YoY, with adj. EBITDA margins1 of 25.9%, primarily due to improvement in domestic pharma and BSV consolidation. Mankind’s chronic share increased by 200bps YoY to 39.3% driven by strong growth of 16.7% in cardiac and 14.4% in anti-diabetes. Revenue from OTC grew by 5.2% in Q3FY26 vs -2.6% in Q2FY26. We expect growth to improve further. BSV growth initiatives progressing well; Strong double-digit growth in Q3. We remain confident of delivering long term sustainable growth anchored by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio.”
Q3 FY26 Performance Summary Revenue from Operations at INR 3,567 Cr, up by 11.5% YoY o Domestic revenue at INR 3,046 Cr, up 11.1%, Exports at INR 521 Cr, up 14.1% YoY Adjusted EBITDA1 margin of 25.9% and PAT margin of 11.6% Diluted EPS2 of INR 9.9 up by 6.7% YoY (FV Re.1)
0 Comments